ArrowArtboardCreated with Sketch.Title ChevronCrossEye IconFacebook IconIcon FacebookGoogle Plus IconLayer 1InstagramCreated with Sketch.Linkedin IconIcon LinkedinShapeCreated with Sketch.Icon Mail ContactPath LayerIcon MailMenu BurgerIcon Opinion QuotePositive ArrowIcon PrintRSS IconIcon SearchSite TitleTitle ChevronTwitter IconIcon TwitterYoutube Icon
Science

Kyoto researchers show gene fix may work

OSAKA -- Kyoto University scientists have found that correcting a genetic defect that causes muscular dystrophy can alleviate the symptoms of the severest form of this debilitating disease.

     Akitsu Hotta and his colleagues used induced pluripotent stem (iPS) cells -- cells reprogrammed to an embryonic state -- to test their hypothesis. While much work remains to turn their discovery into a practical treatment, it does give cause for hope.

     Their findings appear Thursday in the online version of the journal Stem Cell Reports.

     Scientists have known that Duchenne muscular dystrophy, an incurable condition that leads to respiratory and cardiac failure, is the result of a genetic mutation that disrupts the production of a crucial protein.

     The Kyoto University team took iPS cells derived from patient tissue, removed the defective genetic sequence and replaced it with a normal one. When these cells turned into muscle cells, they produced the protein correctly. But iPS cells that did not undergo the genetic repair yielded muscle cells that soon degenerated.

(Nikkei)

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

Get unlimited access
NAR site on phone, device, tablet

You have {{numberReadArticles}} FREE ARTICLE{{numberReadArticles-plural}} left this month

Subscribe to get unlimited access to all articles.

3 months for $9

Get unlimited access
NAR site on phone, device, tablet

Your trial period has expired

You need a subscription to...

See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

See all offers
NAR on print phone, device, and tablet media